Bone Graft and Substitute Market
Vittorio Putti was a founding member of orthopedic science. The first bone grafting operation date back to 1821, in which tissues were grafted from one part to another part of the same via surgery, which was named as autograft, it took place in Germany. Subsequently in 1881, first recorded allograft surgery was performed, in which tissue or organ was transplanted from one individual to another of same species with different genotype. The advancement in bone grafting continued to develop during World War I and World War II, owing to treat injured soldiers with advanced techniques.Both surgical and non-surgical methods were used by surgeons to treat sports injuries, musculoskeletal trauma, spine diseases, infections, etc.
Rising orthopedic surgeries across the globe is a major factor supporting the growth of the bone graft and substitute market. As perthe World Health Organization, total number of orthopedic surgeries across the globeis estimated to be ~418 million in 2016, which is expected to increase by 7.5% by 2020. However, bone grafts are used to stabilize orthopedic implants and provide a scaffold for ingrowth of new bone. As per the International Osteoporosis Foundation, osteoporosis is responsible for~8.9 million fractures in a year at global level. Such statistics support the scope of the global bone graft and substitute market growth.
Rising geriatric population is also acting as a key driver for the market growth, as elderly population are more prone to bone related problems such as osteoporosis which is increasing the growth in global market. As per the National Institute of Health (NIH), in 2015, it was recorded that 8.5% of global population i.e. 617 million people are of age 65 and above, which is expected to reach approximately 1.6 billion by end of 2050. According to United States Census Bureau Countries like Germany, Greece, Japan and Italy together had an average geriatric population of 26% of the world in 2016; geriatric population is rapidly rising in both Asia Pacific and Latin America. Hence, increasing geriatric population across the globe provides significant market growth opportunities for the global bone graft and substitute market for the forecast period.
As per the World Health Organization, total number of orthopedic surgeries across the globe recorded to be 418 million in 2016, which is expected to increase by 7.5% by 2020. 60% of global orthopedic surgeries were carried out in high income regions like Western Europe, North America, Japan, Australia, South Korea etc., as per the Global Health Education Consortium. Moreover, by 2020, total orthopedic procedures across the globe are anticipated to reach over 7.5 million according to American Academy of Orthopedic Surgeon. Increasing amount of orthopedic surgeries would supplement the growth of the global bone graft and substitute market for the forecasted period.
Technological advancement in Orthopedic surgery and bone grafting is playing a significant role. Bone grafting process such as autologous, allogenicand synthetic substrates are contributing substantially. Hybrid material for bone grafting consist of synthetic biomaterials, which have been developed and clinically used. Hybrid material such as synthetic, natural polymer andceramics such as co polymer, polymer – polymer bend, polymer ceramics composites etc. are developed. Increase in number of investments for the development of hybrid material in bone grafting is supporting the market growth. For instance,in 2017, research council of UK invested approx. $133 million for hybrid material development. Furthermore, as per National Health Institute, globally incidence of bone disorders and conditions are expected to be doubled by 2020. Rising number of bone disorders are likely to create the opportunity for the bone grafting and substitute.Thus, increasing investments in the development of hybrid material for bone grafting is creating opportunity for the bone graft and substitute market.
The technological advancements in the healthcare sector such as use of stem cells, 3D printing, and other related innovations have substantially boosted the demand of bone graft and substitute products. These products are minimally invasive in nature, which promotes faster recovery and improves the healing process with less pain in surgery or treatment, these are some key reasons which are supporting the adoption of these advanced products in surgeries. Development in orthobiologicalproducts that includes the use of calcium phosphate-based biomaterials and recombinant human bone morphological proteins (rhBMPs) have also supported the growth of the global bone graft and substitute market. For instance: In 2017, Zimmer biomet introduced X-PSI Knee system that generated a 3D anatomical model for TKA procedures. Moreover, advancement in platelet-rich-plasma (PRP) technology has gained importance in regenerative orthopedic and sports medicines. Advancement in PRP is also expected to be useful in the treatment of regenerating hyaline-like cartilage for knees generative and non-degenerative patients. These advancements in orthobiologic products are driving the global bone graft and substitute market.